Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.1.1.37 (
DNA methyltransferase
)
4,983
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Iroquois homeobox
(IRX) encodes members of homeodomain containing genes which are involved in development and differentiation. Since it has been reported that the
IRX1
gene is localized in a lung cancer susceptibility locus, the epigenetic regulation and function of
IRX1
was investigated in lung carcinogenesis. We observed frequent hypermethylation of the
IRX1
promoter in non-small cell lung cancer (NSCLC) compared to small cell lung cancer (SCLC). Aberrant
IRX1
methylation was significantly correlated with reduced
IRX1
expression. In normal lung samples, the
IRX1
promoter showed lower median DNA methylation levels (<10%) compared to primary adenocarcinoma (ADC, 22%) and squamous cell carcinoma (SQCC, 14%). A significant hypermethylation and downregulation of
IRX1
was detected in ADC and SQCC compared to matching normal lung samples (
p
< 0.0001). Low
IRX1
expression was significantly correlated with impaired prognosis of ADC patients (
p
= 0.001). Reduced survival probability was also associated with higher
IRX1
promoter methylation (
p
= 0.02). Inhibition of
DNA methyltransferase
(
DNMT
) activity reactivated
IRX1
expression in human lung cancer cell lines. Induced DNMT3A and EZH2 expression was correlated with downregulation of
IRX1
. On the cellular level,
IRX1
exhibits nuclear localization and expression of
IRX1
induced fragmented nuclei in cancer cells. Localization of
IRX1
and induction of aberrant nuclei were dependent on the presence of the homeobox of
IRX1
. By data mining, we showed that
IRX1
is negatively correlated with oncogenic pathways and
IRX1
expression induces the proapoptotic regulator
BAX
. In conclusion, we report that
IRX1
expression is significantly associated with improved survival probability of ADC patients.
IRX1
hypermethylation may serve as molecular biomarker for ADC diagnosis and prognosis. Our data suggest that
IRX1
acts as an epigenetically regulated tumor suppressor in the pathogenesis of lung cancer.
...
PMID:Epigenetic Inactivation of the Tumor Suppressor
IRX1
Occurs Frequently in Lung Adenocarcinoma and Its Silencing Is Associated with Impaired Prognosis. 3325 12